Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/73841
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Veloso, Pedro | por |
dc.contributor.author | Machado, Raul | por |
dc.contributor.author | Nobre, Clarisse | por |
dc.date.accessioned | 2021-09-01T16:57:32Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.citation | Veloso, Pedro; Machado, Raul; Nobre, Clarisse, Mesalazine and inflammatory bowel disease from well-established therapies to progress beyond the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 167, 89-103, 2021 | por |
dc.identifier.issn | 0939-6411 | por |
dc.identifier.uri | https://hdl.handle.net/1822/73841 | - |
dc.description.abstract | Summary Inflammatory bowel disease incidence has been constantly rising for the past few decades. Current therapies attempt to mitigate its symptoms since no cure is established. The most commonly prescribed drug for these patients is 5-aminosalicylic acid (5-ASA). Due to the low rate and seriousness of side effects compared to other therapies, 5-ASA is still largely prescribed in many stages of inflammatory bowel disease, including scenarios where evidence suggests low effectiveness. Although commercialized formulations have come a long way in improving pharmacokinetics, it is still necessary to design and develop novel delivery systems capable of increasing effectiveness at different stages of the disease. In particular, micro- and nano-sized particles might be the key to its success in Crohns disease and in more serious disease stages. This review provides an overview on the clinical significance of 5-ASA formulations, its limitations, challenges, and the most recent micro- and nanoparticle delivery systems being designed for its controlled release. Emergent alternatives for 5-ASA are also discussed, as well as the future prospects for its application in inflammatory bowel disease therapies. | por |
dc.description.sponsorship | This work was supported by the strategic programmes UIDB/04469/2020, UIDB/04050/2020, UID/BIA/04050/2019 and Project ColOsH (PTDC/BTM–SAL/30071/2017), funded by national funds through FCT I.P. (Fundação para a Ciência e Tecnologia, Portugal) and ERDF (European Regional Development Fund) via COMPETE2020 – Programa Operacional Competitividade e Internacionalização (POCI, Portugal). R.M. acknowledges FCT I.P. for funding in the scope of the Scientific Employment Stimulus instrument (CEECIND/00526/2018). | por |
dc.language.iso | eng | por |
dc.publisher | Elsevier 1 | por |
dc.relation | UIDB/04469/2020 | por |
dc.relation | UIDB/04050/2020 | por |
dc.relation | UID/BIA/04050/2019 | por |
dc.relation | PTDC/BTM–SAL/30071/2017 | por |
dc.relation | CEECIND/00526/2018 | por |
dc.rights | restrictedAccess | por |
dc.subject | 5-aminosalicylic acid | por |
dc.subject | Mesalazine | por |
dc.subject | Drug delivery | por |
dc.subject | Inflammatory bowel disease | por |
dc.subject | Crohns disease | por |
dc.subject | Ulcerative colitis | por |
dc.title | Mesalazine and inflammatory bowel disease from well-established therapies to progress beyond the state of the art | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/abs/pii/S0939641121002010 | por |
dc.comments | CEB54559 | por |
oaire.citationStartPage | 89 | por |
oaire.citationEndPage | 103 | por |
oaire.citationConferencePlace | Netherlands | - |
oaire.citationVolume | 167 | por |
dc.date.updated | 2021-08-09T13:17:54Z | - |
dc.identifier.doi | 10.1016/j.ejpb.2021.07.014 | por |
dc.date.embargo | 10000-01-01 | - |
dc.identifier.pmid | 34329709 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | - |
dc.subject.wos | Science & Technology | por |
sdum.journal | European Journal of Pharmaceutics and Biopharmaceutics | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series CBMA - Artigos/Papers |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_54559_1.pdf Acesso restrito! | 1,22 MB | Adobe PDF | Ver/Abrir |